NHS Trust harnesses AI to speed up treatment
May 22, 2018Manufacturing and Production, Medical Communications AI, NHS, biotech, drugs, pharma, pharmaceutical
The Royal Liverpool and Broadgreen University Hospitals NHS Trust has teamed up with a provider of AI systems to introduce …
The cause of the most common form of childhood cancer found
May 22, 2018Manufacturing and Production, Research and Development biotech, drugs, leukaemia, pharma, pharmaceutical
Professor Mel Greaves, of The Institute of Cancer Research, has spent 30 years uncovering what is behind the mysterious rise …
ViiV’s two-drug regimen gets EU approval for HIV-1
May 22, 2018Manufacturing and Production, Sales and Marketing EMA, EU, Europe, HIV, Juluca, ViiV Healthcare, pharma
ViiV Healthcare has announced that its HIV therapy Juluca (dolutegravir/rilpivirine) has been awarded marketing authorisation in the EU from the …
Nabriva closes in on bringing new class of antibiotic to market
May 22, 2018Manufacturing and Production, Sales and Marketing Antibiotics, Nabriva Therapeutics, biotech, drugs, pharma, pharmaceutical
Nabriva Therapeutics, a biotech based in Dublin, Ireland, has announced positive Phase 3 data for its antibiotic, lefamulin, which could …
Gilead expands operations in Cork, Ireland
May 21, 2018Manufacturing and Production, Sales and Marketing Gilead, Ireland, biotech, drugs, pharma, pharmaceutical
Gilead has unveiled the expansion of its Cork manufacturing site, involved in the creation of its treatments for HIV and …
Clinical trials, Brexit and the question of ‘full alignment’
May 21, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing brexit, clinical trials, feature, pharma
Gene Matthews, Partner at Leigh Day, reviews the tough decisions the UK has to make regarding its position in the …
EMA review confirms risks of Abbvie and Biogen’s Zinbryta outweigh benefits
May 21, 2018Research and Development, Sales and Marketing EMA, Europe, European Commission, PRAC, multiple sclerosis, pharma, zinbryta
The EMA has judged that the benefits offered by Zinbryta (daclizumab), Abbvie and Biogen’s humanised IgG1 monoclonal antibody for the …
Roche’s Hemlibra stakes claim to be haemophilia market leader
May 21, 2018Research and Development, Sales and Marketing Hemlibra, Roche, Shire, biotech, drugs, haemophilia, pharma, pharmaceutical
Hemlibra was widely expected to become the dominant therapeutic for treating haemophilia patients and its latest clinical trial results only …
FDA approves AZ’s Lokelma for hyperkalaemia
May 21, 2018Sales and Marketing AstraZeneca, FDA, Lokelma, hyperkalaemia, pharma
The FDA has revealed its decision to approve AstraZeneca’s oral potassium-removing agent Lokelma (sodium zirconium cyclosilicate) for the treatment of …
Investigation of kickbacks in Greece sputters to halt
May 21, 2018Sales and Marketing Greece, Novartis, biotech, drugs, pharma, pharmaceutical
Greek parliament has decided against investigating allegations of bribery, involving Novartis and numerous high-level former politicians. The case has dominated …
Top Ten most popular articles on Pharmafile.com this week
May 18, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, FDA, Novartis, Takeda, Trump, brexit, pharma, pharmafile, top ten
The year is flying by – it’s another Friday, and that means another Top Ten run-down.Perhaps the biggest story this …
Ebola threat intensifies in DR Congo
May 18, 2018Medical Communications Ebola, MSD, biotech, drugs, pharma, pharmaceutical
The Ebola outbreak in the Democratic Republic of Congo is becoming increasingly serious, after it was confirmed that there was …
Pfizer’s Lyrica achieves endpoint as adjunct in paediatric epilepsy
May 18, 2018Medical Communications, Research and Development FDA, Lyrica, Pfizer, epilepsy, pharma
Pfizer has revealed new Phase 3 data for its oral epilepsy therapy Lyrica (pregbalin) as an adjunctive treatment for partial …
Amgen/Novartis potential blockbuster migraine med gets FDA nod
May 18, 2018Medical Communications, Sales and Marketing Allergan, Amgen, Novartis, biotech, drugs, migraine, pharma, pharmaceutical
The first in a new class of migraine treatments has just received approval from the FDA; Amgen and Novartis’ Aimovig …
Study finds Herceptin use can be halved
May 17, 2018Medical Communications, Research and Development Herceptin, Roche, biosimilars, biotech, drugs, pharma, pharmaceutical
A team of researchers from the University of Cambridge and Warwick Clinical Trials have revealed that Roche’s Herceptin is just …
Living with an undiagnosed condition
May 17, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing feature, patient experience, pharma
Samantha O’Shea explains some of the challenges she faces caring for her son, Ethan, who lives with a debilitating but …
Europe expands approved indication of Amgen’s Repatha in cardiovascular disease
May 17, 2018Sales and Marketing Amgen, Repatha, cardiovascular disease, pharma
Amgen has revealed that its PCSK9 inhibitor Repatha (evolocumab) has received approval from the European Commission in a new indication: …
Ipsen receives European first-line approval for Cabometyx
May 17, 2018Sales and Marketing Cabometyx, biotech, drugs, ipsen, pharma, pharmaceutical
Ipsen has revealed that it has received approval for the use of Cabometyx for first-line use in patients with advanced …
FDA green lights first non-opioid therapy to manage symptoms of opioid withdrawal
May 17, 2018Sales and Marketing FDA, Lucemyra, opioid crisis, opioids, pharma
As the opioid epidemic continues to grip the US as the leading cause of deaths in those under the age …
UK MPs call for Brexit priority over pharma industry
May 17, 2018Medical Communications ABPI, UK government, biotech, drugs, pharma, pharmaceutical
A new report published by the Business, Energy and Industrial Strategy Committee has called for the UK government to ensure …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
